Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

ng Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics, Inc.
Erica Wishner
Director, Corporate Communications
Cell: 914-282-0836
ewishner@acorda.com
or
Media:
Rooney and Associates Communications
Sean Leous
Cell: 917-715-3765





Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:9/17/2014)... ROSEVILLE, Minn. , Sept. 17, 2014  Rebiotix Inc. ... of the company,s lead product candidate, RBX2660 (microbiota suspension) will ... the IDWeek 2014 conference in Philadelphia ... will be presented during the poster session on Thursday, October ... C. difficile Infection: 60-Day Interim Analysis of the ...
(Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
(Date:9/17/2014)... of people suffer from neck and arm pain as a ... FDA approved the launch of a clinical trial for the ... Spinal Kinetics, which may offer relief to people with cervical ... for Special Surgery (HSS), the number one orthopedic hospital in ... York City and in the Northeast participating in ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
(Date:9/17/2014)... Thompson HealthDay Reporter ... the womb to household chemicals known as phthalates might ... University researchers reported in a new study. Children ... asthma between age 5 and 11 if their mothers ... phthalates (pronounced thal-ates), the researchers found. The two phthalates ...
(Date:9/17/2014)... R.I. [Brown University] As Congress adjourns this month ... senators will step over on their way out the ... Repeal and Medicare Provider Payment Modernization Act of 2014. ... Surgery , Dr. Eli Adashi recounts what he and ... bipartisan bill. The perennial trouble with how Medicare pays ...
(Date:9/17/2014)... Boston Children’s Museum and From ... concert series, introducing young Museum visitors to musicians ... premier national platform celebrating the stories, talents, and ... young musicians featured will also be showcased on ... is fortunate to partner with the wonderful musicians ...
(Date:9/17/2014)... 2014 StartX , a nonprofit ... raising rounds of funding at its Summer Demo Day ... and media, was the first such gathering held at ... the university. The presentations were delivered on an expansive ... Labs, a 2,000 square foot life science facility that ...
(Date:9/17/2014)... 17, 2014 The in vitro diagnostics ... technology market, focusing on molecular diagnostics for conditions such ... genetic testing. The IVD market value is projected to ... of 2017. The major drivers of the market’s growth ... which is evidenced by the explosion for raid and ...
Breaking Medicine News(10 mins):Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... Simon J. ... NJHCFFA. , ... --Simon J. Samaha, M.D., recently was confirmed by the New Jersey State Senate as one of ... (The Authority). , , , , ,Dr. Samaha is the President and Chief Executive Officer of ...
... Perkins Warns Houston "Abortion Super Center" Will Be Prototype ... Jan. 18 An estimated 10,000 people converged on ... across from the nation,s largest abortion facility.  Tony Perkins, president of ... Call to Conscience in Houston today to rally pro-life ...
... to ask simple question of male patients , MONDAY, ... strong warning sign that a man might be at ... problems, a long-running study indicates. , "We saw that ... men with erectile function still had a 40 percent ...
... experts stress that ,senior moments, don,t guarantee that dementia ... News) -- Mental lapses among older adults occur more ... new research finds. , Excessive daytime sleepiness, staring into ... fluctuations that often precede Alzheimer,s, say researchers from Washington ...
... 18 An urgent aid shipment containing 4,000 tents and ... Haitian coastal town of Jacmel. , Jacmel, 30 miles southwest of ... devastated by the recent earthquake with more than 350 people reported ... that 60 percent of buildings were damaged or destroyed. , An ...
... to Run in Honor of People With Cystic Fibrosis , ... Fibrosis Foundation,s most active volunteers will carry the Olympic Torch today in ... Opening Ceremony of the 2010 Olympic Winter Games. , Liz Burns ... than $600,000 for CF research, care and education programs. She is ...
Cached Medicine News:Health News:Simon J. Samaha, M.D., Appointed Public Member of New Jersey Health Care Facilities Financing Authority 2Health News:FRC's Tony Perkins Speaks to Rally of Ten Thousand Across from Nation's Largest Abortion Facility 2Health News:Erectile Dysfunction Predicts Heart Disease 2Health News:Frequent Mental Lapses May Precede Alzheimer's 2Health News:Frequent Mental Lapses May Precede Alzheimer's 3Health News:Haiti: Lifesaving Aid Makes Its Way Through to Quake-Hit Jacmel by Ship 2Health News:Cystic Fibrosis Foundation Volunteer to Carry Torch for Vancouver 2010 Olympic Winter Games 2
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
Provides exceptional resolution and fundus scanning capability. Excellent for small pupil diagnosis and treatment....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... MK-2000 Keratome System provides ... wide range of applications. ... ultra-sharp stainless steel disposable ... sterile and ready to ...
Medicine Products: